Literature DB >> 9337190

Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS).

P Lechat1, S Escolano, J L Golmard, H Lardoux, S Witchitz, J A Henneman, B Maisch, M Hetzel, P Jaillon, J P Boissel, A Mallet.   

Abstract

BACKGROUND: To further evaluate the mechanism of beta-blocker-induced benefits in heart failure, the relationships between bisoprolol-induced hemodynamic effects and survival were studied during the Cardiac Insufficiency BIsoprolol Study (CIBIS). METHODS AND
RESULTS: In 557 patients studied, bisoprolol significantly reduced heart rate (-16.3+/-15.3 versus -1.6+/-13.4 bpm, respectively; P<.001) compared with placebo at 2 months after inclusion in the study. Heart rate change over time had the highest predictive value for survival (P<.01). Left ventricular fractional shortening (LVFS) significantly increased in the bisoprolol group compared with the placebo group 5 months after inclusion (+0.04+/-0.06 versus -0.001+/-0.05, respectively; P<.001; n=160). LVFS change over time was also significantly correlated with further survival (P<.02 by Cox analysis). Using a nonparametric approach, we demonstrated a significant interaction between study treatment group and LVFS over time. Patients who demonstrated improvement of LVFS over time (82% and 51% of patients in the bisoprolol and the placebo groups, respectively; P<.02) were at lower risk, but the hazard did not further decrease with a further increase of fractional shortening, and there was no significant difference between study treatment groups. Finally, it could be demonstrated that each of the three factors (heart rate change over time, LVFS change over time, and bisoprolol treatment) made a specific contribution to mortality rate.
CONCLUSIONS: Preservation of left ventricular function appears to play a key role in the bisoprolol-induced beneficial effects on prognosis in heart failure. Short-term beta-blocker-induced cardiac effects could provide a means to identify those patients who will experience improved survival over the long term.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9337190     DOI: 10.1161/01.cir.96.7.2197

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  36 in total

Review 1.  Potential interests of heart rate lowering drugs.

Authors:  T Laperche; D Logeart; A Cohen-Solal; R Gourgon
Journal:  Heart       Date:  1999-04       Impact factor: 5.994

Review 2.  Bisoprolol: a review of its use in chronic heart failure.

Authors:  Jane K McGavin; Gillian M Keating
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Role of heart rate as a marker and mediator of poor outcome for patients with heart failure.

Authors:  John R Kapoor; Paul A Heidenreich
Journal:  Curr Heart Fail Rep       Date:  2012-06

4.  Ivabradine in heart failure: to SHIFT or not to SHIFT.

Authors:  Andres Schuster; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2011-03

5.  Resting heart rate and the risk of death and cardiovascular complications in patients with type 2 diabetes mellitus.

Authors:  G S Hillis; M Woodward; A Rodgers; C K Chow; Q Li; S Zoungas; A Patel; R Webster; G D Batty; T Ninomiya; G Mancia; N R Poulter; J Chalmers
Journal:  Diabetologia       Date:  2012-05       Impact factor: 10.122

6.  Prediction of beneficial effect of beta blocker treatment in severe ischaemic cardiomyopathy: assessment of global left ventricular ejection fraction using dobutamine stress cardiovascular magnetic resonance.

Authors:  T A M Kaandorp; H J Lamb; J J Bax; E Boersma; E P Viergever; E E van der Wall; A de Roos
Journal:  Heart       Date:  2005-11       Impact factor: 5.994

Review 7.  Dobutamine stress echocardiography: does it predict response to beta-blockers in patients with heart failure?

Authors:  Sripal Bangalore; Khashayar Hematpour; Farooq A Chaudhry
Journal:  Curr Heart Fail Rep       Date:  2006-06

Review 8.  Resting heart rate: a modifiable prognostic indicator of cardiovascular risk and outcomes?

Authors:  J Malcolm Arnold; David H Fitchett; Jonathan G Howlett; Eva M Lonn; Jean-Claude Tardif
Journal:  Can J Cardiol       Date:  2008-05       Impact factor: 5.223

9.  Myocardial perfusion reserve and contractile pattern after beta-blocker therapy in patients with idiopathic dilated cardiomyopathy.

Authors:  R H J A Slart; R A Tio; P A van der Vleuten; T P Willems; D D Lubbers; R A Dierckx; D J van Veldhuisen
Journal:  J Nucl Cardiol       Date:  2010-03-18       Impact factor: 5.952

Review 10.  Heart rate control with adrenergic blockade: clinical outcomes in cardiovascular medicine.

Authors:  David Feldman; Terry S Elton; Doron M Menachemi; Randy K Wexler
Journal:  Vasc Health Risk Manag       Date:  2010-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.